Key MPN trials to look out for in 2025

Prithviraj Bose, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, highlights key myeloproliferative neoplasm (MPN) trial updates from ASH 2024. He highlights trials investigating agents, including a BET inhibitor, a PIM kinase inhibitor, bezuclastinib, and navtemadlin. He also mentions several ongoing Phase III trials that are investigating agents in different MPN settings, including JAK inhibitor failure, suboptimal, frontline, and anemia-directed approaches. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.